Where Science Meets Access
Access by Design™
Scientific depth. Commercial consequence.
A strong clinical programme does not automatically create a strong commercial asset.
Decisions made years before launch — comparator, population, endpoints, subgroups and statistical strategy — can determine future HTA outcomes, access, price and ultimately asset value.
I founded Sur Access to connect those decisions.
Clinical evidence → HTA outcome → probability of access → price → commercial value
Why an independent specialist
My background combines a PhD in Computational Chemistry from ETH Zurich with 17+ years across scientific innovation, regulatory strategy, evidence generation and market access, complemented by health-economics training at the London School of Economics.
This allows me to work across science, regulatory development, HTA and commercial strategy — assessing not only where the evidence gaps are, but which ones matter for access and value.
How I work
Emerging biotech companies rarely need a large market-access team throughout development. They do need senior expertise at the decisions that matter.
With Sur Access, you work directly with me — from the strategic question through the analysis and recommendation.
The principle is simple:
Design the evidence with access in mind.
Because by the time reimbursement begins, many of the decisions that determine access have already been made.
